177 related articles for article (PubMed ID: 23091188)
21. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
Kashuba AD; Tierney C; Downey GF; Acosta EP; Vergis EN; Klingman K; Mellors JW; Eshleman SH; Scott TR; Collier AC
AIDS; 2005 Jan; 19(2):145-52. PubMed ID: 15668539
[TBL] [Abstract][Full Text] [Related]
22. Lopinavir and atazanavir in pregnancy: comparable infant outcomes, virological efficacies and preterm delivery rates.
Perry ME; Taylor GP; Sabin CA; Conway K; Flanagan S; Dwyer E; Stevenson J; Mulka L; McKendry A; Williams E; Barbour A; Dermont S; Roedling S; Shah R; Anderson J; Rodgers M; Wood C; Sarner L; Hay P; Hawkins D; deRuiter A
HIV Med; 2016 Jan; 17(1):28-35. PubMed ID: 26200570
[TBL] [Abstract][Full Text] [Related]
23. An in vitro assay to assess transporter-based cholestatic hepatotoxicity using sandwich-cultured rat hepatocytes.
Ansede JH; Smith WR; Perry CH; St Claire RL; Brouwer KR
Drug Metab Dispos; 2010 Feb; 38(2):276-80. PubMed ID: 19910518
[TBL] [Abstract][Full Text] [Related]
24. Basal efflux of bile acids contributes to drug-induced bile acid-dependent hepatocyte toxicity in rat sandwich-cultured hepatocytes.
Susukida T; Sekine S; Ogimura E; Aoki S; Oizumi K; Horie T; Ito K
Toxicol In Vitro; 2015 Oct; 29(7):1454-63. PubMed ID: 26055650
[TBL] [Abstract][Full Text] [Related]
25. Interaction between HIV protease inhibitors (PIs) and hepatic transporters in sandwich cultured human hepatocytes: implication for PI-based DDIs.
Liu L; Unadkat JD
Biopharm Drug Dispos; 2013 Apr; 34(3):155-64. PubMed ID: 23280499
[TBL] [Abstract][Full Text] [Related]
26. Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects.
Wire MB; McLean HB; Pendry C; Theodore D; Park JW; Peng B
Antimicrob Agents Chemother; 2012 Jun; 56(6):2846-51. PubMed ID: 22391553
[TBL] [Abstract][Full Text] [Related]
27. Species-specific interaction of HIV protease inhibitors with accumulation of cholyl-glycylamido-fluorescein (CGamF) in sandwich-cultured hepatocytes.
Ye ZW; Van Pelt J; Camus S; Snoeys J; Augustijns P; Annaert P
J Pharm Sci; 2010 Jun; 99(6):2886-98. PubMed ID: 20014428
[TBL] [Abstract][Full Text] [Related]
28. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
AIDS; 2005 Apr; 19(7):685-94. PubMed ID: 15821394
[TBL] [Abstract][Full Text] [Related]
29. Hepatocyte-based in vitro model for assessment of drug-induced cholestasis.
Chatterjee S; Richert L; Augustijns P; Annaert P
Toxicol Appl Pharmacol; 2014 Jan; 274(1):124-36. PubMed ID: 24211272
[TBL] [Abstract][Full Text] [Related]
30. Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.
Simpson KN; Jones WJ; Rajagopalan R; Dietz B
Clin Drug Investig; 2007; 27(7):443-52. PubMed ID: 17563124
[TBL] [Abstract][Full Text] [Related]
31. CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir.
Li F; Lu J; Ma X
Drug Metab Dispos; 2012 Jan; 40(1):18-24. PubMed ID: 21953914
[TBL] [Abstract][Full Text] [Related]
32. Identification of Bile Acids Responsible for Inhibiting the Bile Salt Export Pump, Leading to Bile Acid Accumulation and Cell Toxicity in Rat Hepatocytes.
Oizumi K; Sekine S; Fukagai M; Susukida T; Ito K
J Pharm Sci; 2017 Sep; 106(9):2412-2419. PubMed ID: 28552691
[TBL] [Abstract][Full Text] [Related]
33. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
[TBL] [Abstract][Full Text] [Related]
34. [Lopinavir/ritonavir in patients with human immunodeficiency virus infection in special situations].
Tasias M; Aldeguer JL
Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():18-21. PubMed ID: 25542871
[TBL] [Abstract][Full Text] [Related]
35. Cellular accumulation of cholyl-glycylamido-fluorescein in sandwich-cultured rat hepatocytes: kinetic characterization, transport mechanisms, and effect of human immunodeficiency virus protease inhibitors.
Ye ZW; Augustijns P; Annaert P
Drug Metab Dispos; 2008 Jul; 36(7):1315-21. PubMed ID: 18420783
[TBL] [Abstract][Full Text] [Related]
36. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
Pham PA; Flexner C; Parsons T; Vasist L; Fuchs E; Carson K; Agarwala S; Barditch-Crovo P
J Acquir Immune Defic Syndr; 2007 Jun; 45(2):201-5. PubMed ID: 17414932
[TBL] [Abstract][Full Text] [Related]
37. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
[TBL] [Abstract][Full Text] [Related]
38. Bile salt export pump inhibitors are associated with bile acid-dependent drug-induced toxicity in sandwich-cultured hepatocytes.
Ogimura E; Sekine S; Horie T
Biochem Biophys Res Commun; 2011 Dec; 416(3-4):313-7. PubMed ID: 22108051
[TBL] [Abstract][Full Text] [Related]
39. [Positioning of lopinavir/ritonavir in antiretroviral treatment schemes].
Camacho Á; Rivero A
Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():31-4. PubMed ID: 25542874
[TBL] [Abstract][Full Text] [Related]
40. The dual protease inhibitor lopinavir/ritonavir (LPV/r) exerts genotoxic stress on lung cells.
Marima R; Hull R; Dlamini Z; Penny C
Biomed Pharmacother; 2020 Dec; 132():110829. PubMed ID: 33059259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
